Lincomycin microbiology: Difference between revisions
Created page with "__NOTOC__ {{Lincomycin}} {{CMG}}; {{AE}} {{AK}} ==Microbiology== Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in ..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Microbiology== | ==Microbiology== | ||
Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (seeINDICATIONS AND USAGE). | |||
[[Staphylococcus aureus]] (penicillinase- and non-penicillinase producing strains) | |||
'''Streptococcus pneumoniae''' | |||
The following in vitro data are available; but their clinical significance is unknown. | The following in vitro data are available; but their clinical significance is unknown. | ||
| Line 13: | Line 13: | ||
Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials. | Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials. | ||
'''Aerobic gram-positive | '''Aerobic gram-positive cocci:''' | ||
[[Streptococcus pyogenes ]] | |||
[[Viridans group streptococci]] | |||
'''Aerobic gram-positive bacilli:''' | |||
[[Corynebacterium diphtheriae]] | |||
'''Anaerobic gram-positive non-sporeforming bacilli:''' | '''Anaerobic gram-positive non-sporeforming bacilli:''' | ||
[[Propionibacterium acnes]] | |||
'''Anaerobic gram-positive sporeforming bacilli''': | |||
[[Clostridium tetani]] | |||
[[Clostridium perfringens]] | |||
This drug is not active against most strains of Enterococcus faecalis nor against [[Neisseria gonorrhoeae]], [[Neisseria meningitidis]], Haemophilus influenzae or other gram-negative organisms or yeasts. | |||
This drug is not active against most strains of | |||
Cross resistance has been demonstrated between clindamycin and lincomycin. Some cross resistance with [[erythromycin]] including a phenomenon known as dissociated cross resistance or [[macrolide]] effect has been reported. | Cross resistance has been demonstrated between clindamycin and lincomycin. Some cross resistance with[[ erythromycin]] including a phenomenon known as dissociated cross resistance or[[ macrolide]] effect has been reported. | ||
Studies indicate that lincomycin does not share antigenicity with penicillin compounds. | Studies indicate that lincomycin does not share antigenicity with penicillin compounds. | ||
==References== | ==References== | ||
Latest revision as of 20:25, 9 January 2014
| Lincomycin |
|---|
| LINCOCIN®, LINCOMED®, LINCOMIX® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Compatiblity |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Microbiology
Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (seeINDICATIONS AND USAGE).
Staphylococcus aureus (penicillinase- and non-penicillinase producing strains) Streptococcus pneumoniae
The following in vitro data are available; but their clinical significance is unknown.
Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials.
Aerobic gram-positive cocci: Streptococcus pyogenes Viridans group streptococci
Aerobic gram-positive bacilli: Corynebacterium diphtheriae
Anaerobic gram-positive non-sporeforming bacilli: Propionibacterium acnes
Anaerobic gram-positive sporeforming bacilli: Clostridium tetani Clostridium perfringens
This drug is not active against most strains of Enterococcus faecalis nor against Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae or other gram-negative organisms or yeasts.
Cross resistance has been demonstrated between clindamycin and lincomycin. Some cross resistance witherythromycin including a phenomenon known as dissociated cross resistance ormacrolide effect has been reported.
Studies indicate that lincomycin does not share antigenicity with penicillin compounds.
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050317s172lbl.pdf